AtriCure - ATRC Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AtriCure in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ATRC shares.
View ATRC analyst ratings or view top-rated stocks.

4 analysts have issued 1-year price objectives for AtriCure's shares. Their ATRC share price forecasts range from $50.00 to $71.00. On average, they expect the company's share price to reach $60.67 in the next twelve months. This suggests a possible upside of 28.5% from the stock's current price.
View analysts price targets for ATRC or view top-rated stocks among Wall Street analysts.

AtriCure's stock was trading at $44.38 at the beginning of the year. Since then, ATRC shares have increased by 6.4% and is now trading at $47.20.
View the best growth stocks for 2023 here.

AtriCure saw a decrease in short interest in January. As of January 15th, there was short interest totaling 1,290,000 shares, a decrease of 10.4% from the December 31st total of 1,440,000 shares. Based on an average daily trading volume, of 269,100 shares, the days-to-cover ratio is currently 4.8 days. Approximately 2.8% of the shares of the company are sold short.
View AtriCure's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 21st 2023.
View our ATRC earnings forecast.

AtriCure will be holding an earnings conference call on Tuesday, February 21st at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

AtriCure, Inc. (NASDAQ:ATRC) announced its earnings results on Wednesday, November, 3rd. The medical device company reported $2.11 EPS for the quarter, beating analysts' consensus estimates of ($0.28) by $2.39. The medical device company earned $70.46 million during the quarter, compared to the consensus estimate of $68.95 million. AtriCure had a negative net margin of 17.76% and a negative trailing twelve-month return on equity of 12.09%. During the same quarter in the previous year, the firm earned ($0.11) EPS.

AtriCure updated its FY 2022 earnings guidance on Monday, January, 9th. The company provided earnings per share guidance of -$1.12--$1.10 for the period, compared to the consensus earnings per share estimate of -$1.10. The company issued revenue guidance of $330.40 million-$330.40 million, compared to the consensus revenue estimate of $330.06 million.

38 employees have rated AtriCure Chief Executive Officer Michael Carrel on Glassdoor.com. Michael Carrel has an approval rating of 100% among the company's employees. This puts Michael Carrel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 93.0% of employees surveyed would recommend working at AtriCure to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other AtriCure investors own include AbbVie (ABBV), Gilead Sciences (GILD), Amgen (AMGN), Vertex Pharmaceuticals (VRTX), Enterprise Products Partners (EPD), Abbott Laboratories (ABT), Neurocrine Biosciences (NBIX), NVIDIA (NVDA), Pfizer (PFE) and Sarepta Therapeutics (SRPT).

AtriCure trades on the NASDAQ under the ticker symbol "ATRC."

AtriCure's stock is owned by a number of institutional and retail investors. Top institutional investors include Emerald Advisers LLC (1.11%), Emerald Mutual Fund Advisers Trust (0.87%), New York State Common Retirement Fund (0.52%), Peregrine Capital Management LLC (0.34%), Congress Asset Management Co. MA (0.19%) and Oak Ridge Investments LLC (0.13%). Insiders that own company stock include Angela L Wirick, Angela L Wirick, David D Jr Grumhaus, Douglas J Seith, Justin J Noznesky, Justin J Noznesky, M Andrew Wade, Mark A Collar, Mark A Collar, Michael H Carrel, Regina E Groves, Salvatore Privitera, Scott William Drake, Sven Wehrwein, Tonya Austin and Vinayak Doraiswamy.
View institutional ownership trends.

Shares of ATRC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ATRC stock can currently be purchased for approximately $47.20.

AtriCure (NASDAQ:ATRC) has a market capitalization of $2.20 billion and generates $274.33 million in revenue each year. The medical device company earns $50.20 million in net income (profit) each year or ($1.22) on an earnings per share basis.

The company employs 875 workers across the globe.

AtriCure's mailing address is 7555 INNOVATION WAY, MASON OH, 45040. The official website for the company is www.atricure.com. The medical device company can be reached via phone at (513) 755-4100, via email at lynn@gilmartinir.com, or via fax at 513-755-4567.